Beta Drugs Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹9 Cr
QMar 2026
In Mar 2026, Beta Drugs (BETA) reported revenue ₹97 Cr and net profit ₹9 Cr — revenue -1.0% YoY. Also explore BETA share price data to track price trends across different timeframes.
BETA Quarterly Results — Revenue, Profit & EPS Highlights
Beta Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Beta Drugs screener.
- Revenue of ₹97 Cr in Mar 2026 (-23.6% vs Jun 2026, -1.0% vs Mar 2025)
- Net Profit of ₹9 Cr in Mar 2026 (-47.1% vs Jun 2026, +0.0% vs Mar 2025)
- EBITDA of ₹21 Cr in Mar 2026 (-27.6% vs Jun 2026)
- Operating Margin of 19.0% in Mar 2026 (-3.0pp vs Jun 2026)
- Earnings Per Share of ₹8.93 in Mar 2026 (-39.6% vs Jun 2026)
Beta Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BETA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 97 | 127 | 106 | 98 | 103 | -23.6% | -1.0% |
| Net Profit (₹ Cr) | 9 | 17 | 12 | 9 | 12 | - | - |
| EBITDA (₹ Cr) | 21 | 29 | 24 | 19 | 23 | - | - |
| EPS (₹) | 8.93 | 14.78 | 12.10 | 9.40 | 11.59 | - | - |
| Operating Margin (%) | 19.0% | 22.0% | 21.0% | 16.0% | 20.0% | - | - |
BETA Share Price Trend — 1-Year Movement Across Quarterly Results
Beta Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse Beta Drugs financial data for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Mar 2025
98
Sept 2025
106
Jun 2026
127
Mar 2026
97
Net Profit Trend (₹ Cr)
Mar 2025
9
Sept 2025
12
Jun 2026
17
Mar 2026
9
Operating Margin Trend (%)
Mar 2025
16.0%
Sept 2025
21.0%
Jun 2026
22.0%
Mar 2026
19.0%
BETA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Beta Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores